Onconetix, Inc. Files Q2 2024 10-Q Report

TL;DR

Onconetix (ONCO) filed its Q2 10-Q. Formerly Blue Water Biotech.

AI Summary

Onconetix, Inc. filed its 10-Q for the quarterly period ended June 30, 2024. The company, formerly known as Blue Water Biotech, Inc. and Blue Water Vaccines Inc., is incorporated in Delaware and operates in the Pharmaceutical Preparations sector. Its principal business address is in Cincinnati, Ohio.

Why It Matters

This filing provides investors with the latest financial performance and operational updates for Onconetix, Inc. during the second quarter of 2024.

Risk Assessment

Risk Level: low — This is a routine quarterly filing providing financial and operational information, not indicating immediate significant risk.

Key Players & Entities

• Onconetix, Inc. (company) — Registrant
• June 30, 2024 (date) — Quarterly period end date
• Blue Water Biotech, Inc. (company) — Former company name
• Blue Water Vaccines Inc. (company) — Former company name
• 201 E. Fifth Street, Suite 1900, Cincinnati, OH 45202 (location) — Business and mailing address

FAQ

Key Financial Figures

• $0.00001 — ange on which registered Common stock, $0.00001 par value ONCO The Nasdaq Stock Market

Filing Documents

• ea0212631-10q_onconetix.htm (10-Q) — 1343KB
• ea021263101ex31-1_onconetix.htm (EX-31.1) — 12KB
• ea021263101ex31-2_onconetix.htm (EX-31.2) — 12KB
• ea021263101ex32-1_onconetix.htm (EX-32.1) — 4KB
• ea021263101ex32-2_onconetix.htm (EX-32.2) — 4KB
• 0001213900-24-073545.txt ( ) — 8217KB
• onco-20240630.xsd (EX-101.SCH) — 82KB
• onco-20240630_cal.xml (EX-101.CAL) — 80KB
• onco-20240630_def.xml (EX-101.DEF) — 443KB
• onco-20240630_lab.xml (EX-101.LAB) — 759KB
• onco-20240630_pre.xml (EX-101.PRE) — 441KB
• ea0212631-10q_onconetix_htm.xml (XML) — 890KB

Signatures

Signatures 55 i CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (this "Report") contains forward-looking statements that reflect our current expectations and views of future events. The forward-looking statements are contained principally in the sections entitled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations." Readers are cautioned that known and unknown risks, uncertainties and other factors, including those over which we may have no control and others listed in the "Risk Factors" section of this Report, may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by the words "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue" and "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future, although not all forward-looking statements contain these words. These statements relate to future events or our future financial performance or condition and involve known and unknown risks, uncertainties and other factors that could cause our actual results, levels of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking statements. These

forward-looking statements include, but are not limited to, statements about

forward-looking statements include, but are not limited to, statements about: our financial position and estimated cash burn rate; our estimates regarding expenses, future revenues and capital requirements; our ability to continue as a going concern; our need to raise substantial additional capital to fund our operations and repay indebtedness; our ability to commercialize or monetize Proclarix and integrate the assets and commercial operations acquired in the share exchange with Proteomedix AG ("Proteomedix"); the successful development of our commercialization capabilities, including sales and marketing capabilities. our ability to maintain the necessary regulatory approvals to market and commercialize our products; the results of market research conducted by us or others; our ability to obtain and maintain intellectual property protection for our current products; our ability to protect our intellectual property rights and the potential for us to incur substantial costs from lawsuits to enforce or protect our intellectual property rights; ii the possibility that a third party may claim we or our third-party licensors have infringed, misappropriated, or otherwise violated their intellectual property rights and that we may incur substantial costs and be required to devote substantial time defending against claims against us; our reliance on third parties, including manufacturers and logistics companies; our dependence on third parties to develop, market, distribute and sell our products; the success of competing therapies or diagnostics and products that are or become available; our ability to successfully compete against current and future competitors; our ability to expand our organization to accommodate potential growth and our ability to retain and attract, motivate and retain key personnel; the potential for us to incur substantial costs resulting from product liability lawsuits against us and the potential for these product

View Full Filing

View this 10-Q filing on SEC EDGAR